Functional promoter -765 G > C variant in COX-2 gene is associated with the susceptibility of breast cancer in Chinese Han women

Cancer Cell International

Zhi-Jun Dai³  Xi-Jing Wang³  Hong-Tao Ren³  Shuai Lin³  Hai-Tao Guan³  Shu-Qun Zhang³  Yang Zhao³  Di Liu³  Wei Tang²  Xiao-Bin Ma³  Hua-Feng Kang³  Jie Gao¹ 

[1] Department of Nephrology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China;School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi’an 710061, Shaanxi Province, China;Department of Oncology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

关键词: Susceptibility;    Breast cancer;    Polymorphism;    COX-2;    Cyclooxygenase;   

Others  :  792051
DOI  :  10.1186/1475-2867-14-38

 received in 2013-12-31, accepted in 2014-04-30,  发布年份 2014

【 摘 要 】

Background

Cyclooxygenase (COX) is a rate-limiting enzyme in prostaglandins synthesis which exists in two isoforms, COX-1 and COX-2. Over-expression of COX-2 was considered to increase the proliferation and enhance the invasiveness of breast cancer cells. It was suggested that genetic variations in COX-2 could influence its expression. Herein, the present study was aimed to investigate the associations between two mostly studied functional polymorphisms (-765 G > C and 8473 C > T) in COX-2 and breast cancer risk in Chinese Han women.

Methods

In the hospital-based case-control study, 465 breast cancer patients and 799 cancer-free controls were genotyped for the COX-2 -765 G > C and 8473 C > T polymorphisms using TaqMan assay. We estimated odds ratios (ORs) and 95% confidence intervals (95% CIs) using the logistic regression.

Results

Compared with the wild genotype of -765 G > C, we found a statistically significant increased risk of breast cancer associated with the variant genotypes [GC/CC vs. GG: OR = 1.56, 95% CI = 1.11–2.21]. In the stratified analysis, the increased risk was more predominant among the subgroups of younger subjects (OR = 1.61, 95% CI = 1.00–2.61). Furthermore, the variant genotypes were associated with large tumor size (OR = 3.01, 95% CI = 1.47–6.12). No significant association was observed for the 8473 C > T polymorphism.

Conclusions

Our results suggest that the functional -765 G > C polymorphism in the promoter of COX-2 may influence the susceptibility and progression of breast cancer in the Chinese Han population.

【 授权许可】

   
2014 Gao et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
• [2]Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343(2):78-85.
• [3]Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120.
• [4]Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30(3):377-386.
• [5]Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M: The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010, 2010:215158.
• [6]Kalinski P: Regulation of immune responses by prostaglandin E2. J Immunol 2012, 188(1):21-28.
• [7]Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002, 62(6):1676-1681.
• [8]Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, Ali-Seyed M, Lee DF, Bartholomeusz G, Ou-Yang F, Giri DK, Hung MC: Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004, 6(3):251-261.
• [9]Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ: Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002, 277(21):18649-18657.
• [10]Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Margreiter R, Obrist P: Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 2003, 88(4):574-578.
• [11]Dai ZJ, Ma XB, Kang HF, Gao J, Min WL, Guan HT, Diao Y, Lu WF, Wang XJ: Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo. Cancer Cell Int 2012, 12:53. BioMed Central Full Text
• [12]Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ: Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002, 22(10):1631-1636.
• [13]Szczeklik W, Sanak M, Szczeklik A: Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 2004, 114(2):248-253.
• [14]Tang Z, Nie ZL, Pan Y, Zhang L, Gao L, Zhang Q, Qu L, He B, Song G, Zhang Y, Shukui Wang : The Cox-2–1195 G > A polymorphism and cancer risk: a meta-analysis of 25 case-control studies. Mutagenesis 2011, 26(6):729-734.
• [15]Yu KD, Chen AX, Yang C, Qiu LX, Fan L, Xu WH, Shao ZM: Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010, 122(1):251-257.
• [16]Piranda DN, Festa-Vasconcellos JS, Amaral LM, Bergmann A, Vianna-Jorge R: Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study. BMC Cancer 2010, 10:613. BioMed Central Full Text
• [17]Cok SJ, Morrison AR: The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001, 276(25):23179-23185.
• [18]Gao J, Ke Q, Ma HX, Wang Y, Zhou Y, Hu ZB, Zhai XJ, Wang XC, Qing JW, Chen WS, Jin GF, Liu JY, Tan YF, Wang XR, Shen HB: Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A 2007, 70(11):908-915.
• [19]Li F, Ren GS, Li HY, Wang XY, Chen L, Li J: A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer. Clin Oncol (R Coll Radiol) 2009, 21(4):302-305.
• [20]Kang HF, Dai ZJ, Ma XB, Ma L, Jin YF, Liu XX, Wang XJ: A genetic variant in the promoter of APE1 gene (-656 T > G) is associated with breast cancer risk and progression in a Chinese population. Gene 2013, 531(1):97-100.
• [21]Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001, 276(21):18563-18569.
• [22]Hwang D, Scollard D, Byrne J, Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998, 90(6):455-460.
• [23]van Rees BP, Ristimaki A: Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol 2001, 36(9):897-903.
• [24]Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles RA: COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004, 25(6):961-966.
• [25]Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC: Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer 2004, 90(9):1760-1764.